具有里程碑意义的系列:多模式的管理Oligometastatic肉瘤
Sylvie Bonvalot1, Raphael Tetreau2, Carmen Llacer-Moscardo3
1Department of Surgical Oncology, Institut Curie, Paris University, Paris, France. sylvie.bonvalot@curie.fr.
Annals of surgical oncology
|August 30, 2024
概括
瘤转移的中期阶段 - - 瘤转移的中期阶段 - - 可能可以用转移局部治疗 (MLT) 治疗. 这种方法,使用像立体性除性放射治疗 (SABR) 这样的技术,为精选的肉瘤患者提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 手术瘤学手术瘤学
背景情况:
- 寡卵性转移性疾病代表了局部癌症和广泛癌症之间的中间状态.
- 转移局部疗法 (MLT) 涵盖了诸如立体性废除性放射疗法 (SABR),射频废除 (RFA),微波废除 (MWA),冷废除和外科转移切除等技术.
- 将MLT整合到肉瘤治疗中是复杂的,需要仔细选择患者.
研究的目的:
- 审查在转移性肉瘤中受益于MLT的医疗场景.
- 评估各种MLT技术的优缺点.
- 分析关键研究,以确定MLT在临床实践中的作用.
主要方法:
- 对回顾性研究和关键序列的审查.
- 多学科团队 (MDT) 讨论涉及放射瘤学家,外科瘤学家,医学瘤学家和干预放射学家.
- 考虑患者因素:病情,疾病生物学,组织学和负担.
主要成果:
- 追溯数据支持选择患者的MLT.
- 对于MLT的决定,需要MDT的投入来探索所有治疗选择.
- 由于技术的变化和复杂性,建议专门的中心进行MLT.
结论:
- MLT 提供了对小卵性瘤的潜在治愈策略.
- 仔细选择患者和多学科决策对于成功实施MLT至关重要.
- 未来的研究应该集中在生活质量和患者报告的结果上,以优化MLT的作用.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...